Abstract: The proportion of ejection fraction preserved heart failure (HFpEF) in heart failure patients is increasing with the aging population but traditional drugs for the treatment of chronic heart failure fail to significantly improve the prognosis of HFpEF patients. In recent years, it has been observed that ARNI, an angiotensin receptor–neprilysin inhibition, has a definite curative effect on heart failure patients with reduced ejection fraction (HFrEF). ARNI is considered to be possible to improve the current situation of HFpEF patients and the efficacy of ARNI in patients with ejection fraction retention heart failure is highly expected. However, there are only a handful of large-scale clinical studies related to this worldwide. The purpose of this review is to explore the possible mechanism of the action and the therapeutic progress of sacubitril/valsartan, a representative drug of ARNI, in treatment of HFpEF patients.